Go Pro
→ Today's Stock of the Day (From The Early Bird) (Ad)tc pixel Free BBIO Stock Alerts

BridgeBio Pharma (BBIO) Earnings Date, Estimates & Call Transcripts

BridgeBio Pharma logo
$81.50 -1.44 (-1.74%)
As of 08/21/2026 04:00 PM Eastern
Compare

BridgeBio Pharma Earnings Summary

BridgeBio Pharma issued Q2 2026 earnings on August 10, 2026, reporting an EPS of -$0.78, which missed the consensus estimate of -$0.58 by $0.20. Quarterly revenue rose 120.4% year-over-year to $243.68 million, above the consensus estimate of $220.91 million. With a trailing EPS of -$3.57, BridgeBio Pharma's earnings are expected to grow next year, from ($2.62) to ($0.30) per share.

Upcoming Q3
Earnings Date
Oct. 28After Market ClosesEstimated
Consensus EPS
(Aug. 10)
-$0.58
Actual EPS
(Aug. 10)
-$0.78 Missed By -$0.20
Actual Revenue
(Aug. 10)
$243.68M

Q2 2026 Earnings Resources

BBIO Upcoming Earnings

BridgeBio Pharma's next earnings date is estimated for Wednesday, October 28, 2026, based on past reporting schedules.

Powered by Quartr
Get BridgeBio Pharma Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BridgeBio Pharma and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

BBIO Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

BBIO Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

BridgeBio Pharma Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20261-$0.61-$0.61-$0.61
Q2 20261-$0.42-$0.42-$0.42
Q3 20261-$0.38-$0.38-$0.38
Q4 20261$0.14$0.14$0.14
FY 2026 4 -$1.27 -$1.27 -$1.27
Q1 20271$0.11$0.11$0.11
Q2 20271$0.44$0.44$0.44
Q3 20271$0.71$0.71$0.71
Q4 20271$0.92$0.92$0.92

BridgeBio Pharma Earnings History by Quarter

Export
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
10/28/2026
(Estimated)		--------
8/10/2026Q2 2026-$0.5756-$0.78 -$0.2044-$0.78$220.91M$243.68M
5/7/2026Q1 2026-$0.70-$0.84 -$0.14-$0.84$178.07M$194.52M
2/24/2026Q4 2025-$0.75-$1.00 -$0.25-$1.00$150.71M$154.18M
10/29/2025Q3 2025-$0.88-$0.95 -$0.07-$0.95$107.71M$120.70M
8/5/2025Q2 2025-$0.83-$0.95 -$0.12-$0.95$98.46M$110.57M
4/29/2025Q1 2025-$1.00-$0.88+$0.12-$0.88$57.14M$36.74M
2/20/2025Q4 2024-$1.09-$1.31 -$0.22-$1.40$4.04M$5.88M

BridgeBio Pharma Earnings - Frequently Asked Questions

BridgeBio Pharma has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, October 28th, 2026 based off last year's report dates. Learn more on BBIO's earnings history.

In the previous quarter, BridgeBio Pharma (NASDAQ:BBIO) missed the analysts' consensus estimate of ($0.58) by $0.20 with a reported earnings per share (EPS) of ($0.78). Learn more on analysts' earnings estimate vs. BBIO's actual earnings.

The conference call for BridgeBio Pharma's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for BridgeBio Pharma's latest earnings report can be read online.
Read Transcript

BridgeBio Pharma's earnings report can be found in their filing with the SEC.
View SEC filing

BridgeBio Pharma (NASDAQ:BBIO) has a recorded annual revenue of $502.08 million.

BridgeBio Pharma (NASDAQ:BBIO) has a recorded net income of -$724.93 million. BBIO has generated -$3.57 earnings per share over the last four quarters.

BridgeBio Pharma's earnings are expected to grow from ($2.62) per share to ($0.30) per share in the next year.

Related Companies
Earnings Tools

Earnings data for NASDAQ:BBIO is sourced from Fiscal.ai, with the most recent quarter reported on 8/10/2026. New results are added as companies report their earnings.
From Our Partners
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Buffett's Final Warning: "The Dollar Is Going to Hell"
On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going t...
Decentralized Masters | Sponsoredtc pixel